Advanced Medical Science-Planning, Inc (AMS) is a Japanese VC-backed nuclear medicine start-up company seeking to transform Japan’s nuclear industry and provide new business and economic growth opportunities following the March 2011 Fukushima Nuclear Power Station Accident.

Pursuant to our corporate mantra “Cure Better, Innovation,” AMS will deploy nuclear medicine-based Theranostics, which combines both therapeutic and diagnostic capabilities in one dose for cancer treatment, as well as pair Theranostics with artificial intelligence to enhance their effectiveness in terms of Precision Oncology.

In connection with executing our disruptive growth strategy, AMS is presently working in the application process to the Pharmaceutical and Medical Devices Agency (PMDA) on a phased approach to bring the 68Ga-Based PET-Radiopharmaceuticals including 68Ga-PSMA and 68Ga-DOTATOC that are available in Europe and the United States, to Japan. AMS has adopted a unique regulatory approach to obtain marketing approval for the automated synthesizer as a medical device producing the PET-Radiopharmaceuticals, based on our deep understanding of the Act on the Regulation of Radioisotopes and the Medical Care Act, which differs from a common regulatory path among Western countries for radiopharmaceuticals as a drug.

AMS also plans to establish the capability to produce radioisotopes of interest in Japan as part of our overall strategy for Japan and the Asian region. AMS, through its subsidiary Medical Isotope Prime Japan (MIPJ), is also securing long-term, stable supplies of vital medical isotopes such as lead-212 (212Pb) to enable the development of new treatments by Japanese research institutions and hospitals.